NICE’s Reversal On Pfizer’s Inlyta May Boost Faith In Drug Appeals
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has reversed its decision on Pfizer’s Inlyta for renal cell carcinoma following a successful appeal by the U.S. pharma.